Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/15121
Title: Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: A randomized controlled trial
Authors: Erich V. de Paula
Kaan Kavakli
Johnny Mahlangu
Yasmin Ayob
Steven R. Lentz
Massimo Morfini
László Nemes
Silva Z. Šalek
Midori Shima
Jerzy Windyga
Silke Ehrenforth
Ampaiwan Chuansumrit
Universidade Estadual de Campinas
Ege University Medical School
Academic Hospital
National Blood Center
University of Iowa
Azienda Ospedaliera Careggi
National Hemophilia Center
University of Zagreb School of Medicine
Nara Kenritsu Ika Daigaku Fozuku Byoin
Institute of Haematology and Transfusion Medicine, Warsaw
Novo Nordisk AS
Mahidol University
Keywords: Medicine
Issue Date: 1-Jan-2012
Citation: Journal of Thrombosis and Haemostasis. Vol.10, No.1 (2012), 81-89
Abstract: Summary. Background:A recombinant factor VIIa analog (NN1731; vatreptacog alfa [activated]) was developed to provide safe, rapid and sustained resolution of bleeds in patients with hemophilia and inhibitors. Patients/Methods:This global, prospective, randomized, double-blinded, active-controlled, dose-escalation trial evaluated and compared one to three doses of vatreptacog alfa at 5, 10, 20, 40, and 80μgkg -1 with one to three doses of recombinant FVIIa (rFVIIa) at 90μgkg -1 in the treatment of acute joint bleeds in hemophilia patients with inhibitors. The primary endpoint comprised adverse events; secondary endpoints were evaluations of immunogenicity, pharmacokinetics, and efficacy. Results and Conclusions:Overall, 96 joint bleeds in 51 patients ( > 12 years of age) were dosed. Vatreptacog alfa was well tolerated, with a low frequency of adverse events. No immunogenic or thrombotic events related to vatreptacog alfa were reported. A high efficacy rate of vatreptacog alfa in controlling acute joint bleeds was observed; 98% of bleeds were controlled within 9h of the initial dose in a combined evaluation of 20-80μgkg -1 vatreptacog alfa. The efficacy rate observed for rFVIIa (90%) is consistent with data from published clinical trials. The trial was not powered to compare efficacy, and further trials are needed to investigate the efficacy of vatreptacog alfa as compared with that of rFVIIa. The trial was registered at ClinicalTrials.gov (Registration Number: NCT00486278). © 2011 International Society on Thrombosis and Haemostasis.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84855374941&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/15121
ISSN: 15387836
15387933
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.